What is the primary objective of GDPR?

The primary objective of GDPR is to protect the fundamental rights and freedoms of natural persons, particularly their right to the protection of personal data, while ensuring the free movement of personal data within the EU. Enacted as Regulation (EU) 2016/679 and enforceable since May 25, 2018, it replaces the fragmented 1995 Data Protection Directive by establishing uniform rules through its directly applicable nature. Core principles under Article 5 include lawfulness, fairness and transparency; purpose limitation; data minimisation; accuracy; storage limitation; integrity and confidentiality; and accountability, requiring controllers to demonstrate compliance.

Who is legally or professionally required to comply with GDPR?

GDPR applies to any controller or processor established in the EU, or any non-EU entity offering goods/services to or monitoring the behaviour of EU data subjects, regardless of location. Article 3 defines this extraterritorial scope, capturing entities processing personal data—any information relating to an identifiable natural person, including IP addresses or genetic data. Public authorities and organisations conducting large-scale systematic monitoring or special-category data processing must appoint a Data Protection Officer (DPO) under Article 37.

Does GDPR require an external audit or third-party certification?

No, GDPR does not mandate external audits or third-party certification for compliance. Article 42 encourages voluntary certification mechanisms and seals as proof of compliance, but these are optional. Organisations must self-demonstrate adherence via Records of Processing Activities (ROPA) (Article 30), Data Protection Impact Assessments (DPIAs) for high-risk processing (Article 35), and accountability measures, subject to supervisory authority oversight.

How often should an assessment for GDPR be performed?

GDPR requires ongoing, risk-based assessments rather than fixed intervals, with DPIAs conducted prior to high-risk processing and reviewed if risks change. Article 35 mandates DPIAs for systematic monitoring or large-scale special-category data processing, while Article 32 demands continuous evaluation of security measures considering the state of the art, costs, and processing context. Breach assessments trigger 72-hour notifications under Articles 33-34.

What are the consequences of non-compliance with GDPR?

Non-compliance with GDPR can result in administrative fines up to €20 million or 4% of total global annual turnover, whichever is higher, for severe infringements. Article 83 establishes two tiers: up to €10 million or 2% for lesser violations (e.g., records obligations). Supervisory authorities issue corrective orders, reprimands, or bans; the European Data Protection Board (EDPB) ensures consistency via the one-stop-shop mechanism (Article 56). Landmark fines include €50 million on Google (2019).

An GDPR be mapped to other international frameworks?

Yes, GDPR principles such as accountability, data subject rights, and lawful processing bases align with frameworks like Brazil's LGPD, California's CCPA/CPRA, and Japan's APPI. Its global influence stems from the extraterritorial scope, inspiring adequacy decisions (Article 45) for countries like Japan. Core mappings include consent, purpose limitation, and breach notification, though divergences exist in opt-in/opt-out models and penalty scales.

What is the first step to begin implementing GDPR?

The first step to implement GDPR is to conduct a comprehensive data mapping and inventory of all personal data processing activities. This identifies controllers/processors, legal bases (Article 6), and risks, enabling ROPA creation (Article 30) and determination of DPO needs (Article 37). Embed privacy by design and by default (Article 25) from this baseline.

What is the primary objective of FDA 21 CFR Part 11?

The primary objective of FDA 21 CFR Part 11 is to establish criteria under which the Agency considers electronic records and electronic signatures trustworthy, reliable, and equivalent to paper records and handwritten signatures (§11.1(a)). This equivalency enables electronic methods while ensuring authenticity, integrity, availability, and non-repudiation through controls like validation (§11.10(a)), audit trails (§11.10(e)), access limitations (§11.10(d)), and electronic signature requirements (§§11.50–11.300).

Who is legally or professionally required to comply with FDA 21 CFR Part 11?

FDA 21 CFR Part 11 applies to organizations using electronic records created, modified, maintained, archived, retrieved, or transmitted under predicate rules, or submitted electronically to FDA (§11.1(b)). It targets life sciences firms (pharma, biotech, devices) relying on electronic records in lieu of paper for regulated activities, or where electronic versions are relied upon despite paper existence; exclusions apply to certain food records (§11.1(f)–(p)).

Oes FDA 21 CFR Part 11 require an external audit or third-party certification?

No, FDA 21 CFR Part 11 does not require external audits or third-party certification. Compliance is demonstrated through internal controls, validation (§11.10(a)), SOPs, training (§11.10(i)), and inspection readiness (§11.1(e)), with systems and documentation available for FDA review; FDA's 2003 guidance emphasizes risk-based enforcement without mandating external validation.

How often should an assessment for FDA 21 CFR Part 11 be performed?

FDA 21 CFR Part 11 does not specify a frequency for assessments, but they must align with change control, periodic reviews, and risk-based validation lifecycles (§11.10(k)). Organizations implement ongoing monitoring via SOPs, with reassessments triggered by system changes, annual management reviews, or inspection findings to ensure continued fitness for use.

What are the consequences of non-compliance with FDA 21 CFR Part 11?

Non-compliance with FDA 21 CFR Part 11 results in FDA enforcement actions including Form 483 observations, warning letters, product holds, and injunctions, as predicate rules remain fully enforceable. The 2003 guidance notes continued enforcement of access controls, checks, training, signatures, and documentation, with data integrity failures leading to recalls or submission rejections.

An FDA 21 CFR Part 11 be mapped to other international frameworks?

FDA 21 CFR Part 11 is not explicitly mapped to other frameworks in its text or 2003 guidance, focusing solely on U.S. predicate rules. Organizations may align controls risk-based for efficiency, but compliance stands alone without regulatory harmonization statements.

What is the first step to begin implementing FDA 21 CFR Part 11?

The first step to implement FDA 21 CFR Part 11 is to establish a formal applicability framework mapping predicate rules to records and assessing business reliance on electronic versions. Document scope decisions in SOPs per 2003 guidance, classifying systems as closed (§11.3(b)(4)) or open (§11.3(b)(9)) to prioritize controls.

Standards Comparison

GDPR vs FDA 21 CFR Part 11

GDPR

Mandatory

2016

EU regulation for personal data protection and privacy

FDA 21 CFR Part 11

Mandatory

1997

FDA regulation for electronic records and signatures equivalence

Quick Verdict

GDPR mandates comprehensive personal data protection for EU residents globally, while FDA 21 CFR Part 11 ensures electronic records' trustworthiness in life sciences. Companies adopt GDPR for privacy compliance and Part 11 for FDA-regulated digital equivalence.

Data Privacy

GDPR

Regulation (EU) 2016/679 General Data Protection Regulation

Cost

€€€

Complexity

Medium

Implementation Time

18-24 months

Key Features

Extraterritorial scope applies to non-EU entities targeting EU residents
Accountability principle requires demonstrable compliance measures
Fines up to 4% of global annual turnover for violations
Enhanced data subject rights including right to erasure
72-hour mandatory personal data breach notification

Electronic Records

FDA 21 CFR Part 11

21 CFR Part 11 Electronic Records; Electronic Signatures

Cost

€€€€

Complexity

High

Implementation Time

12-18 months

Key Features

Secure computer-generated time-stamped audit trails
Controls for closed and open systems
Electronic signature manifestation and linking
Risk-based system validation requirements
Unique multi-component signature controls

Detailed Analysis

A comprehensive look at the specific requirements, scope, and impact of each standard.

GDPR Details

What It Is

Regulation (EU) 2016/679, known as the General Data Protection Regulation (GDPR), is a directly applicable EU law enacted in 2016 and enforceable since May 25, 2018. It modernizes data privacy, replacing the 1995 Data Protection Directive, with extraterritorial scope applying to any entity processing EU residents' data. Its risk-based, accountability-driven approach mandates lawful processing bases and demonstrable compliance.

Key Components

Seven core principles: lawfulness, purpose limitation, data minimization, accuracy, storage limitation, integrity/confidentiality, accountability.
Enhanced data subject rights (access, rectification, erasure, portability, objection).
Obligations like Data Protection Officers (DPOs), Data Protection Impact Assessments (DPIAs), 72-hour breach notifications.
Enforcement via fines up to €20M or 4% global turnover; no formal certification but ongoing compliance.

Why Organizations Use It

Legal obligation for EU data processors; reduces breach risks, builds trust, enables global data flows. Enhances reputation, avoids penalties, supports Digital Single Market competitiveness.

Implementation Overview

Involves gap analysis, policy updates, training, DPIAs, DPO appointment. Applies universally to controllers/processors handling EU data; high complexity for SMEs/multinationals; continuous audits required.

FDA 21 CFR Part 11 Details

What It Is

FDA 21 CFR Part 11 is a U.S. federal regulation establishing criteria for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using electronic systems for predicate-rule-required records. The approach is risk-based, with narrowed scope per 2003 FDA guidance emphasizing enforcement discretion for certain controls while upholding core requirements.

Key Components

Subparts A-C cover scope, electronic records (closed/open systems controls like validation, audit trails, access), and signatures (manifestation, linking, uniqueness).
~20 key controls including secure audit trails, authority checks, training, and documentation.
Built on ALCOA+ principles for data integrity; no formal certification, but compliance via validation and inspection readiness.

Why Organizations Use It

Meets legal obligations for electronic recordkeeping in pharma, devices, biotech.
Mitigates data integrity risks, avoids warning letters, enables digital transformation.
Builds stakeholder trust, accelerates inspections, improves efficiency.

Implementation Overview

Risk-based CSV (GAMP5): scoping, validation (IQ/OQ/PQ), SOPs, training.
Applies to life sciences firms; multi-phase (6-18 months); audited via FDA inspections.

Key Differences

Aspect	GDPR	FDA 21 CFR Part 11
Scope	Personal data protection and privacy rights	Electronic records and signatures trustworthiness
Industry	All sectors processing EU personal data globally	FDA-regulated life sciences and healthcare
Nature	Mandatory EU regulation with fines	US FDA regulation with enforcement discretion
Testing	DPIAs for high-risk processing	Risk-based system validation IQ/OQ/PQ
Penalties	Up to 4% global turnover fines	Warning letters, product holds, enforcement actions

Scope

GDPR

Personal data protection and privacy rights

FDA 21 CFR Part 11

Electronic records and signatures trustworthiness

Industry

GDPR

All sectors processing EU personal data globally

FDA 21 CFR Part 11

FDA-regulated life sciences and healthcare

Nature

GDPR

Mandatory EU regulation with fines

FDA 21 CFR Part 11

US FDA regulation with enforcement discretion

Testing

GDPR

DPIAs for high-risk processing

FDA 21 CFR Part 11

Risk-based system validation IQ/OQ/PQ

Penalties

GDPR

Up to 4% global turnover fines

FDA 21 CFR Part 11

Warning letters, product holds, enforcement actions

Frequently Asked Questions

Common questions about GDPR and FDA 21 CFR Part 11

GDPR FAQ

FDA 21 CFR Part 11 FAQ

You Might also be Interested in These Articles...

Your Guide to Implementing PCI DSS in Your Organization

Step-by-step guide to implementing PCI DSS in your organization. Achieve compliance, protect cardholder data, and reduce risks. Start securing payments today!

Unpacking the True Cost: A Guide to Calculating TCO for Modern Compliance Monitoring Software

Unpack the true Total Cost of Ownership (TCO) for compliance monitoring software. Factor in licenses, implementation, training, maintenance, and ROI savings for

The Panoramic View: How Integrated Compliance Monitoring Creates Unprecedented Organizational Visibility and Adaptability

Gain unprecedented organizational visibility with integrated compliance monitoring. Automate real-time alerts, ensure GDPR & SOC 2 adherence, reduce risks, and

Run Maturity Assessments with GRADUM

Transform your compliance journey with our AI-powered assessment platform

Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

100+ Standards & Regulations

AI-Powered Insights

Collaborative Assessments

Actionable Recommendations

Explore More Comparisons

See how GDPR and FDA 21 CFR Part 11 compare against other standards

Other GDPR Comparisons

Other FDA 21 CFR Part 11 Comparisons

What It Is

Key Components

Seven core principles: lawfulness, purpose limitation, data minimization, accuracy, storage limitation, integrity/confidentiality, accountability.

Enhanced data subject rights (access, rectification, erasure, portability, objection).

Obligations like Data Protection Officers (DPOs), Data Protection Impact Assessments (DPIAs), 72-hour breach notifications.

Enforcement via fines up to €20M or 4% global turnover; no formal certification but ongoing compliance.

What It Is

Key Components

Subparts A-C cover scope, electronic records (closed/open systems controls like validation, audit trails, access), and signatures (manifestation, linking, uniqueness).

~20 key controls including secure audit trails, authority checks, training, and documentation.

Built on ALCOA+ principles for data integrity; no formal certification, but compliance via validation and inspection readiness.

Aspect

GDPR

FDA 21 CFR Part 11

Scope

Personal data protection and privacy rights

Electronic records and signatures trustworthiness

Industry

All sectors processing EU personal data globally

FDA-regulated life sciences and healthcare

Nature

Mandatory EU regulation with fines

US FDA regulation with enforcement discretion

Testing

DPIAs for high-risk processing

Risk-based system validation IQ/OQ/PQ

Penalties

Up to 4% global turnover fines

Warning letters, product holds, enforcement actions